FHTX
$5.06
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses i...
Recent News
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Beats Revenue Estimates
Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of -19.72% and +14.87%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Verastem (VSTM) Reports Q4 Loss, Beats Revenue Estimates
Verastem (VSTM) delivered earnings and revenue surprises of -2.04% and +0.20%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Foghorn Therapeutics CEO Talks Lilly-Partnered SMARCA2 Phase 1 and New Degrader Targets at Conference
Foghorn Therapeutics (NASDAQ:FHTX) President and CEO Adrian Gottschalk said the company was built around the idea that chromatin regulation—and specifically the BAF (SWI/SNF) chromatin remodeling complex—represents a broad and clinically relevant set of oncology targets that have historically been d
Is Foghorn Therapeutics (NASDAQ:FHTX) In A Good Position To Deliver On Growth Plans?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 133.27% as Wall Street Analysts Expect?
The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to a 133.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.